Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 15 people enrolled
- Started
- 29 Jan 2021
- Ended
- 16 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tranexamic Acid
- 0.9% sodium chloride
- Record updated
- 20 December 2024
- Why it stopped
- Per sponsor
Who can take part
- Age
- Up to 24 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Participant undergoing limb salvage procedure of malignant bone tumor of the distal femur or proximal tibia, which typically requires blood transfusions
- Patient under the age of 25
- Adequate bone marrow function defined as:; Upward trending peripheral absolute neutrophil count (ANC); Platelet count ≥ 100,000/mm\^3 (transfusion independent defined as no platelets required for 4 days); Hemoglobin ≥ 8.0 g/dL; No RBC transfusion within 24 hours
- Adequate renal function defined as:; Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73m\^2 OR; Maximum serum creatinine based on age/gender as follows: Age 1 day to < 1 years: maximum serum creatinine (mg/dL) 0.6 for males and 0.5 for females; Age 1 to < 2 years: maximum serum creatinine (mg/dL) 0.6 for males and 0.6 for females; Age 2 to < 6 years: maximum serum creatinine (mg/dL) 0.8 for males and 0.8 for females; Age 6 to < 10 years: maximum serum creatinine (mg/dL) 1.0 for males and 1.0 for females; Age 10 to < 13 years: maximum serum creatinine (mg/dL) 1.2 for males and 1.2 for females; Age 13 to < 16 years: maximum serum creatinine (mg/dL) 1.5 for males and 1.4 for females; Age ≥ 16 years: maximum serum creatinine (mg/dL) 1.7 for males and 1.4 for females
- Adequate liver function defined as:; Total bilirubin ≤ 1.5x the institutional upper limit of normal (IULN) for age; ALT (SGPT) and AST (SGOT) ≤ 2.5x IULN for age (or <5x IULN for patients with documented disease involving the liver or 10x IULN for patients receiving HDMTX); Serum albumin > 2 g/dL
- Adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5
- Female participants of child-bearing potential (>10 years old) must have a negative serum or urine pregnancy test within 72 hours of sedation
Who cannot take part
- Participants receiving erythropoietin-stimulating agents (e.g. epoetin alfa)
- Participants actively receiving all-trans retinoic acid (ATRA) or isotretinoin (Accutane)
- Participants currently on anticoagulation medications (e.g. warfarin, enoxaparin)
- Persisting toxicity related to other systemic therapies (e.g. chemotherapy) which constitutes an unacceptable safety risk based on the judgment of the PI and/or the primary treating physician
- Female participants who are currently receiving estrogen-based contraception therapy
- Participants enrolled in another clinical trial utilizing an IND/IDE experimental therapy
- Participants with known allergies to antifibrinolytics
- Personal history of a thrombosis or active thrombus
- Participants with a history of seizures. Patients with a history of febrile seizure are eligible
- Participants with a history of CNS disease
- Participants with known bleeding disorder
- Participants with known platelet dysfunction
- Participants whose limb salvage procedure may require significant manipulation of major blood vessels
- Participants with known bone marrow deficiency resulting in red blood cell deficiency (e.g. Diamond-Blackfan anemia)
- Participants with active hemorrhagic cystitis (e.g. alkylator-induced) with gross hematuria or >50 RBCs per high powered field on urinalysis
- Participants with known hypercoagulopathies
- Female participants who are currently pregnant or actively breastfeeding
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent
Where in United States
- St. Jude Children's Research HospitalMemphis, United States
About the trial
What the trial wants to find out
This is a randomized double-blind control trial evaluating the use Tranexamic acid (TXA) to decrease blood loss and transfusion requirements in pediatric and young adult cancer patients undergoing a limb salvage procedure that frequently requires perioperative or post-operative transfusions of blood products.
Read full original descriptionShow less
Primary Objective
* To evaluate the difference in intra-or post-operatively transfused blood volume (mL/kg) for patients undergoing limb salvage procedures of the distal femur or proximal tibia who are randomized to receive perioperative tranexamic acid (TXA) versus placebo.
Secondary Objectives
* To evaluate changes in platelets and in hemoglobin from pre-op to post-op level for patients randomized to receive perioperative TXA versus placebo. * To evaluate differences in post-operative daily surgical drain output for patients randomized to receive perioperative TXA versus placebo. * To evaluate changes in estimated blood loss (EBL) for patients randomized to receive perioperative TXA versus placebo. * To evaluate the association between the intra-or post-operatively transfused blood volume and estimated blood loss (EBL) for patients randomized to receive perioperative TXA and placebo, respectively.
Exploratory Objectives
* To evaluate differences in functional outcomes post-operatively for patients randomized to receive perioperative TXA versus placebo. * To explore if significant correlations are observed between parameters reported with rotational thromboelastometry (ROTEM®) and EBL and transfusion requirements in pediatric and young adult patients undergoing limb salvage procedure who are randomized to perioperative TXA versus placebo. * To evaluate differences in the prevalence and management of wound complications such as superficial or periprosthetic infections, wound dehiscence, contact dermatitis, post- operative hematomas, or any other clinically significant wound complication between patients randomized to receive perioperative TXA versus placebo.
The 2 groups in the trial
- Tranexamic AcidTreatment being tested
At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
- PlaceboPlacebo, for comparison
At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
Treatment: 0.9% sodium chloride
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tranexamic Acid (TXA) to Reduce Volume Of Blood Transfused In Pediatric And Young Adult Cancer Patients Undergoing Limb Salvage Procedure Of A Lower Extremity
- Record updated
- 20 December 2024